Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study

Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study

Background/Aims Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery. Vedolizumab is an anti-integrin antibody that is increasingly used given that i...

Celý popis

Podrobná bibliografie
Hlavní autoři: Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
Médium: Článek
Jazyk:English
Vydáno: Korean Association for the Study of Intestinal Diseases 2022-01-01
Edice:Intestinal Research
Témata:
vedolizumab
ulcerative colitis
surgical complications
crohn disease
inflammatory bowel disease
On-line přístup:http://irjournal.org/upload/pdf/ir-2020-00117.pdf

Internet

http://irjournal.org/upload/pdf/ir-2020-00117.pdf

Podobné jednotky